Citations

Clear

3047 citation(s) found for "Lévy, Patrick".

Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68 Gallium ‐ DOTATATE positron emission tomography
Coston, Tucker W , Mahadevia, Himil J , Hochwald, Alex , Accurso, Joseph M , Sharma, Akash , Johnson, Geoffrey B , Ashman, Jonathan B. , Sonbol, Mohamad B , McGarrah, Patrick , Halfdanarson, Thorvardur R , Starr, Jason

Mayo Clinic

Journal of Neuroendocrinology | October 27, 2026 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/jne.70301 | PMID 42944559 Get It

Abstract Tumors of neuroendocrine origin are a heterogenous group of related neoplasms which can arise from anywhere in the body. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status and grade (Ki‐67 expression and/or mitotic rate), with significant prognostic variability accordingly. Historically, the prevalence of bone metastasis is reported to be 6%–12% based on “first generation” (i.e., 111 Indium pentetreotide [Octreoscan®]) somatostatin receptor imaging (SSRI). We conducted a retrospective cohort study including patients with well‐differentiated NENs to determine the clinical and imaging characteristics of osseous metastases when evaluated with higher‐sensitivity 68 Gallium‐DOTATATE positron emission tomography (PET) scans, as well as determining fracture prevalence in selected sub‐cohorts. We also developed a risk score analysis to assess risk of fracture in this cohort. Four hundred twenty‐four patients were identified for inclusion. The median age was 61 years. Most patients were asymptomatic (64%), had sclerotic lesions (77%), Krenning 4 (71%), and had >3 sites (69%) of osseous disease. A high proportion of patients had osseous metastases at sites with high risk for fracture, including vertebra (82%), pelvis (63%), and peri‐trochanteric femur (34%). Fifty‐seven patients (13%) in the entire cohort suffered a fracture. Fracture prevalence was significantly lower in small bowel neuroendocrine tumors (NETs, 7%) and Grades 1 and 2 disease (8% and 9%, respectively), with higher prevalence in pancreatic NETs, paragangliomas/pheochromocytomas, lung carcinoid, and Grade 3 disease (≥20% for each; p ‐values <.05). Our study showed that the rate of osseous metastatic disease approximates 20% in well‐differentiated NENs. Most bone metastases are asymptomatic and the risk of fracture is variable based on the primary site of disease and tumor grade. Our novel risk score analysis for fracture was designed to assist clinician decision making as to management of bone metastasis in this patient population.
Special populations require special research approaches
Crowley, Patrick D , Siegel, Leslie , Dickinson, Drew T , Lahr, Brian , Whalen, Francis X. , Challener, Douglas

Mayo Clinic

Clinical Infectious Diseases | October 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag675 | PMID 42956821 Get It

The hospice setting is unique for patient care and requires different techniques to study than other populations.
Hemagglutinin and fusion proteins precede measles virus ribonucleoproteins and marshal cell-to-cell spread in airway epithelium
Sinn, Patrick L

Mayo Clinic

Microbiology Spectrum | October 14, 2026 | Volume: 14 | Issue: 11 | Pages: No page available

10.1128/spectrum.02297-26 | PMID 42872813 Get It

ABSTRACT Measles virus (MeV) is the most contagious human respiratory pathogen. To understand how it spreads in the airways, we infected well-differentiated primary cultures of human airway epithelial cells (HAE). We discovered that the MeV attachment protein (hemagglutinin, H), the fusion (F) protein, and the assembly organizer protein (matrix, M) reach newly infected cells ahead of, and independently from, the replicative complex proteins. To characterize the mechanisms of MeV spread, we generated a replication-deficient adenoviral vector expressing the MeV M, F, and H proteins in a doxycycline-inducible manner. This viral vector formed infectious centers that preserved epithelial function like those from MeV infection. To further dissect this process, we generated Ad vectors expressing individual MeV proteins, termed Ad-M, Ad-F, and Ad-H. Transduction of HAE with single, double, and triple Ad vector combinations revealed that Ad-F and Ad-H are necessary and sufficient to form MeV-like infectious centers. MeV enters and spreads within airway epithelia via H protein binding to adherens junction protein, nectin-4. To disrupt spread, we introduced the point mutation H Y543A , a mutation previously described to inhibit nectin-4 binding, in the Ad-H vector. Co-transduction of Ad-F and Ad-H Y543A did not result in MeV-like infectious center formation. Finally, we assessed whether the MeV-related paramyxovirus Nipah (NiV) attachment and fusion proteins (G and F, respectively) support cell-to-cell spread. Co-transduction of HAE with Ad-NiV-G and Ad-NiV-F did not result in infectious center formation, suggesting that decoupling of the membrane fusion apparatus function from replication is a unique feature of the MeV envelope glycoproteins. IMPORTANCE Measles virus is a highly contagious pathogen. We characterized a mechanism by which measles virus spreads rapidly through the cells that line the human airway in an ex vivo model. We show that the proteins of the viral membrane fusion apparatus, hemagglutinin (H) and fusion (F), move independently from and reach newly infected cells before the proteins of the replicative complex. Thus, viral protein spread is assembled and arranged in order (i.e., marshaled ). Using adenovirus-based vectors, we show that co-expression of H and F proteins promotes rapid sequential spread to multiple cells and the formation of infectious centers. Further elucidation of the mechanism of measles virus amplification and cell-to-cell spread within the lung may help explain its highly contagious nature.
Deep Neural Network–Driven Early Recognition in Cardiopulmonary Failure: A Paradigm Shift Underway in Temporary Mechanical Circulatory Support?
Tukacs, Monika , Bignami, Elena Giovanna , Wieruszewski, Patrick M , D'Andria Ursoleo, Jacopo , Swol, Justyna

Mayo Clinic

Artificial Organs | October 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/aor.70265 | PMID 42855857 Get It

ABSTRACT The contemporary intensive care unit generates an overwhelming magnitude of high‐frequency, granular physiological data. However, conventional decision‐making for patients requiring temporary mechanical circulatory support (tMCS) remains tethered to reactive, threshold‐driven manual adjustments, underutilizing continuous data streams and failing to optimize the complex patient–machine interaction. This review examines the integration of deep neural networks (DNNs) as a candidate strategy for advanced clinical decision support. By identifying a continuous “digital phenotype,” hierarchical deep learning architectures signal a shift toward real‐time trajectory recognition in tMCS. We establish a four‐tier functional taxonomy—prognosticative, descriptive, predictive, and prescriptive—to categorize translational milestones from automated pump‐speed optimization to closed‐loop homeostatic regulation. Operational challenges are analyzed through the TEIP (Transparency, Explainability, Interpretability, and Performance) Core‐Lens Framework, navigating the dynamic equilibrium between computational density and clinical explainability. We further evaluate the evolving global regulatory landscape, advocating for a foundation on verified empirical safety and rigorous clinical trial validation over absolute mathematical transparency in high‐density architectures. Implementing a strategic roadmap including context‐specific validation, multimodal integration, and human‐centered design is quintessential to safely transform passive hardware into intelligent systems. As the field evolves, DNN technology offers a consequential opportunity to advance early cardiopulmonary failure recognition into a clinical reality.
Intrahepatic Tissue‐Resident CD8 + T‐Cell Programmes Associate With Fibrosis and Local Immune Remodelling in Autoimmune Hepatitis
Stary, Victoria , Losek, Sarah , Mairinger, Magdalena , Prager, Gerhard , Santol, Jonas , Starlinger, Patrick , Reiberger, Thomas , Stättermayer, Albert F. , Stary, Georg

Mayo Clinic

Liver International | October 6, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1111/liv.70897 | PMID 42834625 Get It

ABSTRACT Background and Aims Autoimmune hepatitis is an immune‐mediated liver disease characterized by chronic inflammation and progressive fibrosis. Tissue‐resident memory T cells mediate organ‐specific immunity, but their role in autoimmune hepatitis remains poorly understood. We characterized tissue‐residency‐associated T‐cell populations and their cytokine profiles, assessed associations with disease severity and determined whether these signatures were reflected in peripheral blood. Methods Paired blood and liver samples were obtained from 19 patients with autoimmune hepatitis. Comparator cohorts included 20 patients with metabolic dysfunction‐associated steatotic liver disease and 20 surgical patients providing non‐inflamed adjacent non‐tumorous liver tissue. Multiparameter flow cytometry assessed tissue‐residency markers, T‐cell differentiation and cytokine production after polyclonal stimulation. Immune phenotypes were correlated with histological and clinical parameters. Results Autoimmune hepatitis was associated with compartment‐specific remodelling of T‐cell differentiation states and intrahepatic enrichment of CD8 + T cells expressing CD69, CD103 and CXCR6 relative to paired blood and comparator liver tissues. Intrahepatic CD8 + T cells exhibited an interferon‐γ‐dominant cytokine profile, whereas CD4 + T cells showed broader interferon‐γ‐, interleukin‐17A‐ and interleukin‐4‐associated responses. Despite the enrichment of tissue‐residency‐associated CD8 + T cells, cytokine‐producing CD8 + T‐cell populations with and without a tissue‐resident memory phenotype contributed comparably to the hepatic T‐cell compartment. Tissue‐residency‐associated phenotypes correlated positively with Ishak fibrosis stage, whereas the frequency of interferon‐γ‐positive intrahepatic CD8 + T cells correlated inversely with fibrosis. Conclusions Autoimmune hepatitis was characterized by intrahepatic accumulation of phenotypically distinct and functionally active CD8 + tissue‐resident memory T cells associated with fibrosis. This immune profile was not reflected in paired blood, indicating compartmentalized hepatic immune remodelling.
The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study
Sahwan, Oudai , Mohamed, A , Jamal, Fares , Alsulaiman, Abdullah A , Bauernfeind, Jennah J , McGarrah, Patrick , Starr, Jason , Halfdanarson, Thorvardur R , Sonbol, Mohamad B

Mayo Clinic

Journal of Neuroendocrinology | October 5, 2026 | Volume: 38 | Issue: 10 | Pages: No page available

10.1111/jne.70278 | PMID 42833281 Get It

Abstract Everolimus 10 mg daily is the standard dose for advanced neuroendocrine tumors (NETs), but adverse events frequently necessitate dose reduction. As a result, oncologists often adopt a dose‐escalation strategy starting at 5 mg and increasing the dose as tolerated. In this multicenter study, we evaluated the effect of reduced dose (RD) and standard dose (SD) everolimus on survival, progression, and toxicity in patients with advanced NETs. We conducted a multicenter retrospective cohort study of patients with advanced NETs treated with everolimus at Mayo Clinic and University Hospitals (Cleveland, OH). Patients were grouped by starting dose (5 mg vs. 10 mg). Primary endpoints were overall survival (OS), real‐world progression‐free survival (rwPFS), and adverse events. Multivariable Cox models, inverse probability of treatment weighting (IPTW), and time‐varying dose sensitivity analysis were used to account for confounding and dose crossover. Among 170 patients (48 started on 5 mg; 122 on 10 mg), the 5 mg cohort was older, had worse ECOG PS, and was more heavily pretreated. Median OS was 43.7 months (5 mg) versus 81.5 months (10 mg; log‐rank p = .02). However, after multivariable adjustment ( N = 124 G1–G2 patients; 51 events), the association was no longer statistically significant (adjusted HR, 0.59; 95% CI, 0.31–1.12; p = .11). Median rwPFS was 7.0 versus 12.4 months (log‐rank p = .05); the adjusted rwPFS difference was not statistically significant (HR, 0.95; 95% CI, 0.56–1.61; p = .84). Nearly half (46.7%) of 10 mg starters required dose reduction. Any‐grade toxicity was more common with 10 mg (89% vs. 75%; p = .05). The apparent survival advantage of standard‐dose everolimus was substantially attenuated after adjustment. These findings do not establish dose equivalence and should be interpreted in the context of limited statistical power. Given its more favorable observed tolerability profile, RD everolimus warrants prospective evaluation as a starting strategy for patients at increased risk of treatment‐related toxicity who may not tolerate SD.
Long term clinical performance and analytical robustness of the Lumipulse plasma p‐tau217 assay in routine clinical practice
Ashrafzadeh-Kian, Susan, Bornhorst, Joshua A. , Vanderboom, Patrick M. , Callison, Sarah, Algeciras-Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | September 29, 2026 | Volume: 22 | Issue: 10 | Pages: No page available

10.1002/alz.71887 | PMID 42805946 Get It

Abstract INTRODUCTION Plasma phosphorylated tau 217 (p‑tau217) immunoassays are increasingly being used to assess Alzheimer's disease (AD) pathology despite limited data affirming test reliability over time. METHODS Clinical performance of the Fujirebio Lumipulse G p‑tau217 assay was assessed in 744 Mayo Clinic patients presenting for evaluation of cognitive impairment between July 2024 and December 2025. Cerebrospinal fluid p‑tau181/amyloid beta 42 or amyloid positron emission tomography, within 1 year of p‐tau217 testing, were used as reference. Analytical robustness was evaluated by tracking result frequencies over time, conducting quality control checks, performing 10 lot‑to‑lot comparisons, and comparing two versions of reagents. RESULTS Diagnostic accuracy for detection of AD pathology was 93% (95% confidence interval 91–95) with 23% intermediate results. Reduced estimated glomerular filtration rate was associated with increased intermediate results among amyloid‐negative individuals. Result frequencies remained stable, average imprecision was 8%, and analytical bias between lots and version changes were ≤ 11%. DISCUSSION The findings support plasma p‐tau217 reliability in clinical practice for evaluation of cognitively impaired individuals.
Intratunnel Anchor Fixation and Transtibial Pull‐Through Repair Show Comparable Short‐Term Outcomes After Meniscus Root Repair: A Propensity‐Matched Comparative Study
Tagliero, Adam J. , Ahmad, Rana A. , Mikula, Jacob D. , Hevesi, Mario, Smith, Patrick A. , Krych, Aaron J. , Krych, Aaron J , Tagliero, Adam

Mayo Clinic

Arthroscopy | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70601 | PMID 42782213 Get It

Purpose To compare short‐term outcomes of intratunnel anchor fixation versus transtibial pull‐through repair for meniscus root tears with a minimum of 12‐month follow‐up. Methods Patients who underwent primary meniscus root repair between 2011 and 2024 at a single institution were retrospectively reviewed. Inclusion criteria consisted of primary medial or lateral meniscus root repair using either intratunnel anchor fixation or transtibial pull‐through repair, availability of preoperative radiographs, and completion of postoperative patient‐reported outcome measures with a minimum of 12‐month follow‐up. The groups were propensity‐matched by age, sex, body mass index, operative side, root laterality, and concomitant procedures. Baseline radiographic characteristics (hip‐knee‐ankle angle and posterior tibial slope) were measured. Outcomes included Lysholm score, International Knee Documentation Committee score, Tegner activity score (preoperative and postoperative), Visual Analog Scale for pain at rest and with activity, satisfaction, subjective surgical outcome, and reoperations. Results Fifty patients who underwent intratunnel anchor fixation (mean age, 44 years) were propensity‐matched to 100 patients who underwent transtibial pull‐through repair (mean age, 41 years). Mean follow‐up was 1.5 years (range, 1.0‐2.3) in the intratunnel anchor group and 6.1 years (range, 2.7‐13.7) in the transtibial pull‐through group. Reoperation rates were 8% and 14%, respectively ( P = .43), with repair failure occurring in 4% and 6% ( P > .99). Preoperative and postoperative Tegner scores were similar between groups. Tegner minimal clinical important difference was 0.8, and 26.5% of intratunnel anchor patients achieved this compared with 0% of transtibial pull‐through patients. Patients in the intratunnel anchor cohort reported slightly lower Visual Analog Scale pain with activity (1.8 vs 2.5, P = .02). Postoperative Lysholm (87 vs 83, P = .05) and International Knee Documentation Committee scores (79 vs 76, P = .09) were comparable between groups. A greater proportion of intratunnel anchor patients achieved Patient Acceptable Symptomatic State compared with transtibial pull‐through patients for Visual Analog Scale with activity (74% vs 56%, P = .03) and Lysholm (66% vs 47%, P = .01). Most patients in both cohorts rated their outcome as “much better” or “slightly better” ( P = .49), and satisfaction scores were high. Conclusions At short‐term follow‐up, both the intratunnel anchor and transtibial pull‐through techniques showed high patient satisfaction and comparable overall clinical outcomes. There were no differences in reoperation rates between techniques. Level of Evidence Level III, retrospective comparative case series.
Non‐Invasive Imaging Assessment of Liver Fibrosis
Navin, Patrick J. , Welle, Christopher L. , Pepin, Kay , Yin, Meng , Venkatesh, Sudhakar K. , Pepin, Kay M, Venkatesh, Sudhakar K , Yin, Meng , Navin, Patrick

Mayo Clinic

Journal of Medical Imaging and Radiation Oncology | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/1754-9485.70184 | PMID 42734051 Get It

ABSTRACT Chronic liver disease (CLD) is a major cause of global morbidity and mortality, with outcomes closely linked to the severity of liver fibrosis. While liver biopsy has historically been the reference standard for fibrosis staging, its invasiveness, sampling variability and limited suitability for longitudinal monitoring have driven the widespread adoption of non‐invasive tests (NITs). Imaging‐based biomarkers, particularly elastography, now play a central role in the clinical assessment and care pathway design. This review focuses on imaging techniques for non‐invasive assessment of liver fibrosis, with emphasis on elastography techniques: vibration‐controlled transient elastography (VCTE), ultrasound‐based shear wave elastography (SWE) and magnetic resonance elastography (MRE). Technical principles, advantages, limitations and implementation considerations are discussed to support informed selection across clinical contexts. VCTE offers rapid point‐of‐care assessment with extensive validation for identifying advanced fibrosis but is limited by operator dependence, reduced repeatability and lack of anatomical information. SWE provides real‐time, radiologist‐controlled assessment with improved applicability in obesity and ascites, though intervendor variability and operator dependence remain challenges. MRE demonstrates the highest diagnostic accuracy, reproducibility and technical success, with assessment of larger liver volume and strong performance across etiologies, albeit with limited access due to the requirement of an MRI system. Adjunct MRI biomarkers, including proton‐density fat fraction and iron‐corrected T1 mapping, further enhance liver phenotyping by characterising steatosis and fibro‐inflammatory activity. Understanding the strengths and limitations of each technique is essential for radiologists supporting multidisciplinary CLD management and service implementation, particularly in evolving healthcare environments such as Australia.
Relationship between Antibiotic Prescription and Survival in Hospice
Crowley, Patrick , Siegel, Leslie R. , Dickinson, Drew T. , Lahr, Brian D. , Whalen, Francis X. , Challener, Douglas W. , Crowley, Patrick D , Siegel, Leslie

Mayo Clinic

Clinical Infectious Diseases | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag561 | PMID 42725640 Get It

Abstract Background At hospice enrollment, patients are asked preferences regarding antibiotic use. Limited evidence on how these medications impact survival makes it difficult for clinicians to offer clear guidance. To support decision-making and antimicrobial stewardship, we assessed the association between antibiotic use and survival in outpatient hospice patients. Methods The association between antibiotic use and survival was evaluated using a time-dependent Cox proportional hazards model, adjusted for age, sex, Charlson Comorbidity Index, and hospice-qualifying conditions (HQCs). The cohort included patients enrolled in a large health system’s outpatient hospice program between June 20, 2017, and January 1, 2023. Results Among 6169 patients with an HQC, 1233 received at least one antimicrobial prescription during the study period. The median time from hospice enrollment to first prescription was 16 days (IQR 3-83). Antimicrobial prescribing patterns varied by HQC category. In time-dependent Cox models, antibiotic use was associated with increased hazard of death (aHR 1.47; 95% confidence interval [CI], 1.37–1.57).Stratified analyses showed the strongest association with increased mortality in patients with cancer HQCs (aHR 1.67; 95% CI, 1.50–1.87) and a survival benefit in those with infectious HQCs (aHR 0.60; 95% CI, 0.40–0.89). Discussion Physicians, patients, and families often overestimate the benefits of antibiotics near the end of life. The observed increase in mortality shortly after antibiotic initiation suggests that symptoms prompting antibiotic use may reflect the dying process rather than treatable infection. Knowledge of the limited role of antibiotics in prolonging life in hospice settings may improve decision-making and enhance the quality of end-of-life care.